About Us | Our Journey | MedGenome Labs Ltd
Toll Free Number: 1800 103 3691
Hours: 8:00 AM - 8:00 PM, Monday to Saturday
Closed on public holidays and Sundays

About Us

MedGenome is a Global Leader in Genetic Testing services, Genomics Research and drug discovery solutions. MedGenome has been committed to deliver world class genomic solutions with greater precision and accuracy to empower every human being for better management of their health since 2013.

MedGenome is the only CAP accredited Genetic testing lab in India that offers 1300+ genetic tests backed by the best and the latest testing technologies available across the world. MedGenome is dedicated to bringing the best precision testing solutions for quicker and smarter diagnosis of complex diseases.

We are working towards democratizing the access of quality and affordable genetic solutions to serve over 4 billion people for their healthcare needs through the power of genetic testing.

We operate the largest College of American Pathologists (CAP) accredited Next Generation Sequencing(NGS) lab in South East Asia housing cutting-edge genome sequencing platforms such as Illumina’s NovaSeq, HiSeq X, MiSeq, etc.

OUR FOOTPRINT
covers the whole of India and parts of South Asia covering 250+ serviceable locations
with over
3500
hospitals
and
more than
9000
clinicians leveraging
our services
We currently offer
more than
1300
genetic testing

across several disease categories such as pediatrics, neurology, oncology, hematology, endocrinology, nephrology, ophthalmology, etc.

MedGenome Promise:

  • Science is our DNA
  • Innovation is our Focus
  • Precision is our Expertise
  • Human Impact is our Vision

Our Expertise

We have a team of molecular biologists, geneticists, data scientists and bioinformaticians who drive our genomics research. We have successfully built research pipelines addressing immune oncology, biomarker discovery, companion diagnostics and population-based genomic studies that tap the rich Indian diverse genotype.

  • Largest CAP-accredited and NABL-certified Genomics sequencing lab in South Asia
  • 2,50,000+ Exomes and Genomes sequenced
  • First and only Lab with CAP accreditation for Whole Genome and Whole Exome Testing
  • 1300+ Genetic tests across various diseases categories
  • 700+ Clinical Geneticists, Genome Analysts, Bioinformatics Engineers
  • Founded GenomeAsia 100K, an initiative to sequence 100K individuals of Asian descent
  • Successfully tested about 40,000 NIPT samples with no false-negative
  • First lab to offer Whole-genome sequencing for M.tb
  • First Validated Liquid Biopsy (OncoTrack) in India
  • First in India to introduce Tumor mutation burden (Cancer Agnostic Marker), Clinical Exome, and Whole Exome testing.
We are the founding member of
GENOMEASIA 100K
an initiative to sequence
200,000+ Genomes
in Asia.
We have worked extensively on building clinical databases of
more than
1 Million
patients through collaborations.
We have a repository of clinical, phenotypic and genomics data for
more than
170,000
patients
to provide insights into complex diseases at the genetic and molecular level.
We have access to data that provides insights into genetic diversity of Indian population for
more than
4,500
population groups.

Innovation

Innovation is a core belief and many of our tests have been developed in-ouse including our comprehensive gene panels. We believe in continuous innovation to help reduce the cost of genetic tests and empower clinicians with actionable clinical insights to provide better outcomes. Our liquid biopsy test OncoTrack for monitoring cancer treatment is the only NGS-based ctDNA test available in India.

We hold several IPs that include Clinical Exome, TB testing, Liquid Biopsy, Tumour Mutation Burden, and many such tests developed for various diseases. We have also launched India centric Carrier Screening Test for couples planning a baby. In the Rare Disease segment, we offer Whole Exome, Clinical Exome and TrioExome sequencing test for identifying gene mutations that cause rare diseases.

MedGenome has entered strategic partnerships to provide best in class tests like Non-Invasive Prenatal Test(NIPT), Infectious Diseases and several other companion diagnostics partnerships with leading pharmaceutical companies.

Accreditations

As a firm believer in quality, MedGenome adheres to the highest international standards when it comes to our services and have obtained the prestigious CAP accreditation for our main lab in Bangalore.

Our Journey

  • Series A
    funding of
    $4m led by Emerge
    Ventures
  • Single gene
    tests - MiSeq
  • Small gene
    panels
  • Exome
    sequencing –
    all genes
  • Gene Panels
  • HiSeq
  • Series B
    funding of
    $20m led by
    Sequoia
  • NIPT – Non
    Invasive
    Prenatal
    testing
  • HLA
    matching –
    for
    transplants
  • Genome Asia
    100k
  • PGS – for IVF
  • Series C1
    funding
    $40m led by
    Sequoia India
    and Sofina,
    Zodius
    Capital &
    HDFC
  • Carrier
    screening test
  • Liquid biopsy
  • CAP
    accreditation,
    Bangalore lab
  • Comprehensive
    (SNVs, CNVs &
    fusions)
  • Solid & liquid
    tumor panels
  • Coronary
    Artery
    Disease
    (Polygenic
    risk score)
  • Infectious
    diseases
    portfolio
    including TB
  • $55m Series
    C2 funding
    led by
    Leapfrog
  • Comprehensive
    TB Portfolio
    (Routine and
    Molecular)
  • ICMR approved
    Lab for Covid
    Testing
  • Series C3
    funding of
    $16.5m led
    by IFC World
    Bank Group
  • Launched
    Personal
    Genomics
    Division -
    Genessense
  • Additional
    Cancer Tests

2013

  • Series A funding of $4m led by Emerge Ventures
  • Single gene tests - MiSeq
  • Small gene panels

2014

  • Exome sequencing – all genes
  • Gene Panels
  • HiSeq

2015

  • Series B funding of $20m led by Sequoia
  • NIPT – Non Invasive Prenatal testing
  • HLA matching – for transplants

2016

  • Genome Asia 100k
  • PGS – for IVF

2017

  • Series C1 funding $40m led by Sequoia India and Sofina, Zodius Capital & HDFC
  • Carrier screening test
  • Liquid biopsy
  • CAP accreditation, Bangalore lab

2018

  • Comprehensive (SNVs, CNVs & fusions)
  • Solid & liquid tumor panels

2019

  • Coronary Artery Disease (Polygenic risk score)
  • Infectious diseases portfolio including TB

2020

  • $55m Series C2 funding led by Leapfrog
  • Comprehensive TB Portfolio (Routine and Molecular)
  • ICMR approved Lab for Covid Testing

2021

  • Series C3 funding of $16.5m led by IFC World Bank Group
  • Launched Personal Genomics Division - Genessense
  • Additional Cancer Tests

Awards and Recognition

Economic Times Healthworld
India Diagnostics Award
Best Standalone
Diagnostics
(South)- 2021
The Healthcare
Technology report
Top 25 Health Technology
CEOs of Asia- 2020
Economic Times Healthworld
India Diagnostics Award
Outstanding Research
in Diagnostics
(National)- 2020
Startup 50 by
Smart CEO -
2019
Asia Red Herring
Top 100 - 2019
Economic Times
Now Rise with India
Making of Developed India
Award - 2017
Business World
Disruptor
Healthcare - 2017

Kokilaben
Dhirubhai Ambani
group - 2017
Indıan Express
India’s Top Emerging
Companies - 2016
Bangalore India Bio
Emerging Company
of the Year - 2016
World CSR and Sustainability
Certificate of Merit
Leadership in advanced
precision medicine in
healthcare- 2015
ABP News
Healthcare leadership
award - 2015

Management

Directors

Mahesh Pratapneni

Group CEO &
Co-Founder, Director
View

Dr. Felix Olale

Leapfrog
Director
View

Sam Santhosh

Founder, Director
View

Neeraj Bhargava

Independent Director
View

Tejeshwi Sharma

Sequoia Capital
Director
View

Investors

Test Menu

Genetic Counselling

Microsites

Collaterals

Contact Us

Test Menu

Genetic Counselling

Microsites

Collaterals

Contact Us